Takeda Pharmaceutical Company (B), The Millennium Acquisition Case Solution
Yasuchika Hasegawa, president of Takeda Pharmaceutical Company, dreamt to make Takeda a leading tier company in oncology by 2015. In 2008, Takeda got Millennium Pharmaceuticals, a reputable oncology company with yearly sales of $528 million in 2007 and an appealing pipeline of brand-new drugs. Hasegawa and Millennium CEO Deborah Dunsire thought that it was vital to communicate a constant vision for the future of Millennium within Takeda and assist Millennium staff members feel favorable about the company's future. Century would run separately and end up being Takeda's "Center of Quality in Oncology." This case checks out the actions that Hasegawa required to effectively incorporate Millennium. His concerns fixated maintaining Millennium skill and resolving the friction that developed from 2 extremely various business cultures. He likewise utilized the chance to change Takeda's threat averse culture into a more ingenious and versatile one that would support Takeda ending up being a genuinely international pharmaceutical company. Likewise see OB83, Takeda Medication Company (A): Ending up being a Worldwide Company and OB83(C), Takeda Pharmaceutical Company (C): The Future of Takeda.
This is just an excerpt. This case is about Business
Related Case Solutions & Analyses:
Northwest Airlines: Brush with Bankruptcy (C)–March-June 1993
Siemens Corp. (B): Corporate Advertising for 1996
American Airlines (B): Compensation and Cost Reduction
Thompson Asset Management
Naina Lal Kidwai: Investing in Her Country
Dabur India Ltd. – Globalization
NEW CORPORATE GOVERNANCE IN CANADA. MAJORITY VOTING, INDIVIDUAL VOTING, AND GENDER
SUPPLY CHAIN HUBS IN GLOBAL HUMANITARIAN LOGISTICS
ENTRY OF STARBUCKS IN INDIAN MARKET
SUDA ELECTRIC VEHICLE COMPANY: PRIVATE EQUITY INVESTMENT IN CHINA
